Search
FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement
We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).
Read moreFaculty Information
We are honored that you have agreed to be part of the faculty for the EHA-ISHBT Hematology Tutorial, to be held on March 1-3, 2024 in Hyderabad, India.
Read moreResearch trainings
Old ways won't open new doors. Via non-pecuniary awards, EHA strives to accelerate the careers of promising post-docs in translational or clinical research.
Read moreSplenic marginal zone lymphoma study update, February 2024
A project update from Dr Ahmed Ludvigsen Al-Mashhadi. I am truly grateful for this opportunity provided by EHA, and for EHA's effort in advancing research in a field that may otherwise be very difficult to explore.
Read moreEHA-ISHBT Hematology Tutorial
Date: March 1-3, 2024
Format: In-Person
Location: Hyderabad, India
Chairs: P. K.
Registration & accommodation
Registration is closed. The EHA-EBMT 6th European CAR T-cell Meeting provides opportunities for students, trainees, nurses and others to join the meeting for a discounted fee.
Read moreEHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms
Join us for this unique and rare opportunity and exchange ideas with MDS, MPN, and AML experts in one meeting. Internationally renowned experts will provide presentations and share the recent developments and answers to your clinical questions.
Read more